Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Mutations in Gene Show Predisposition to Artery-Damaging Disease

By LabMedica International staff writers
Posted on 20 Dec 2016
Scientists have discovered that loss-of-function alterations in the YY1AP1 gene can lead to fibromuscular dysplasia (FMD) or similar arterial diseases, including Grange syndrome. More...
The link helps explain what causes this class of arterial disease, which often strikes without warning, as there is currently no test to assess risk of developing FMD.

“This is an important step in understanding the underlying molecular mechanisms of this unexplained and puzzling condition that often affects women,” said Dianna Milewicz, MD, PhD, University of Texas Health Science Center at Houston (Houston, TX, USA), who led the team that made the discovery, “The finding is a critical step in developing treatments.”

The study involved a family with a rare genetic disorder, Grange syndrome, which is also characterized by abnormal cell development on arterial walls. Grange syndrome is characterized by severe and early onset FMD-like arterial disease. “When we compared the chromosome sequence of family members with and without Grange syndrome, we identified mutations in a gene, called YY1AP1, in affected individuals,” said Dongchuan Guo, PhD, the study’s lead author and an associate professor at McGovern Medical School.

Mutations in YY1AP1 causing Grange syndrome were confirmed in additional unrelated families. The team also confirmed their findings through cell biology studies and performed genetic testing involving 282 people with FMD and a control cohort. “This is a good example of how the investigation of a very rare genetic condition that has been identified in only a few individuals can lead to a better understanding of a more common medical problem such as FMD, which may benefit a broader population,” said Dorothy K. Grange, MD, study co-author and a professor at Washington University School of Medicine.

FMD can involve the arteries going to and within the brain, leading to strokes and transient ischemic attacks; it can affect the arteries going to the kidneys, leading to high blood pressure. When doctors suspect a person has FMD, they typically order imaging to see if they can locate the narrowed artery or arteries. While there is no cure, in severe cases, doctors insert tiny wires or catheters into the blood vessels to widen them.

“Diagnosis and treatment of patients with FMD remains a clinical challenge. The recent discovery of Dr. Milewicz and her team is a significant leap toward better understanding of the causative factors in this mysterious disease,” said Ali Azizzadeh, MD, chief of vascular and endovascular surgery at McGovern Medical School.

“YY1AP1 mutations predispose to vascular lesions characteristic of FMD, thus indicating that FMD can result from mutations in a single gene,” the authors wrote, “Thus, these data provide insight into the pathogenesis of FMD, an unusual and poorly understood vascular disease.”

The study, by Guo DC et al, was published December 8, 2016, in the journal The American Journal of Human Genetics.

Related Links:
University of Texas Health Science Center at Houston


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.